Sana biotechnology announces invited oral presentation at the 85th annual american diabetes association scientific sessions

Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes
SANA Ratings Summary
SANA Quant Ranking